| abstract |
A novel 4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide pharmaceutical composition is provided. An IR spectrum having a melting point of 170-174 ° C .; peaks at 1170, 925, 844 and 729 cm −1 and no significant peak at 723 cm −1 ; and a diffraction angle 2θ of 4- [5-Methyl-3-phenylisoxazol-4-yl] showing X-ray powder diffractograms with peaks at 12.221, 15.447, 17.081, 19.798 and 23.861 degrees Pharmaceutical compositions comprising benzenesulfonamide crystals are useful as pharmaceuticals in solid form for treating or preventing cyclooxygenase-2 related disorders. [Selection figure] None |